Wellmind Calming
FDA Label NDC 62795-1043

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Medinatura Inc for the product Wellmind Calming (NDC 62795-1043). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding keep out of reach of children, uses, warnings, directions, purpose, active ingredients, inactive ingredients, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Keep Out Of Reach Of Children

KEEP OUT OF REACH OF CHILDREN

Uses

For the temporary relief of simple nervous tension and anxiousness to promote better natural sleep.

Warnings

Warnings: Do not give to children under 12 years of age.If pregnant or breast-feeding, ask a health professional before use. KEEP OUTOF REACH OF CHILDREN.  If symptoms persist or worsen, a health professional should be consulted. Do not use if known sensitivity to WellMind or any of it's ingredients exists.

Directions

For max absorption, dissolve under tongue. Can be chewed and swallowed. At first sign of symptoms: Adults and children 12 years and older: 1 tablet every ½ to 1 hour until symptoms lessen, then continue with standard dosage.Standard dosage: Adults and children 12 years and older: take 2 tablets in the moning and 2 tablets in the evening. For children under 12 years, consult your health professional.  

Purpose

Calmer Minds

Sleep Deeper

Active Ingredients

Chamomilla 2X, Coffea cruda 10X, Humulus lupulus 2X, Ignatia amara 8X, Moschus 10X,
Nux-vomoica 30X, Passiflora incarnata 2X, Sulphur 12X, Valeriana officinalis 2X, Veratrum album 4X

Inactive Ingredients

*Dextrose, *Lactose, Magnesium Stearate, *Maltodextrin
*contains one or more of these ingredients.

* Please review the disclaimer below.